亚行CHMINACA CAS 1185887-13-1 ADB-CHMINACA（也称为MAB-CHMINACA）是一种基于吲唑合成大麻素。 它是与Ki的结合亲和力= 0.289纳米的CB1受体的强效激动剂和辉瑞在2009年最初是作为镇痛药物。 它在混合大麻素被确定在日本2015年年初。
ADB-CHMINACA CAS 1185887-13-1
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.